Janux Therapeutics Inc
|Market Cap (Intraday)||1.29B|
|2yr Forward PE||N/A|
Janux Therapeutics Inc Stock, NASDAQ:JANX
Janux Therapeutics, Inc. operates preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in La Jolla, CA.